CORDA Investment Management LLC. raised its holdings in Pfizer Inc. (NYSE:PFE) by 1.7% during the first quarter, HoldingsChannel reports. The firm owned 664,914 shares of the biopharmaceutical company’s stock after buying an additional 11,125 shares during the period. Pfizer comprises about 2.2% of CORDA Investment Management LLC.’s investment portfolio, making the stock its 21st biggest holding. CORDA Investment Management LLC.’s holdings in Pfizer were worth $24,089,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. increased its stake in Pfizer by 2.2% in the first quarter. BlackRock Inc. now owns 405,733,970 shares of the biopharmaceutical company’s stock valued at $14,699,742,000 after purchasing an additional 8,760,458 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Pfizer by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock valued at $2,383,700,000 after acquiring an additional 6,965,496 shares in the last quarter. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter valued at about $2,219,532,000. Morgan Stanley boosted its holdings in shares of Pfizer by 16.4% in the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock valued at $1,973,389,000 after acquiring an additional 7,540,245 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 42,009,283 shares of the biopharmaceutical company’s stock valued at $1,546,362,000 after acquiring an additional 2,012,367 shares in the last quarter. Institutional investors own 64.22% of the company’s stock.
PFE has been the topic of several analyst reports. Mizuho reaffirmed a “neutral” rating and issued a $42.00 target price on shares of Pfizer in a report on Wednesday, May 12th. TheStreet raised shares of Pfizer from a “c+” rating to a “b-” rating in a report on Monday, May 3rd. SVB Leerink boosted their price objective on shares of Pfizer from $39.00 to $43.00 and gave the stock a “market perform” rating in a report on Wednesday, May 5th. Berenberg Bank reissued a “neutral” rating and set a $38.00 price objective on shares of Pfizer in a report on Tuesday, March 23rd. Finally, The Goldman Sachs Group set a $45.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, May 24th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average target price of $39.73.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.15. The company had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $13.41 billion. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. Pfizer’s revenue was up 44.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.80 earnings per share. Analysts forecast that Pfizer Inc. will post 3.69 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.90%. The ex-dividend date of this dividend was Thursday, May 6th. Pfizer’s dividend payout ratio is currently 70.27%.
In other news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the sale, the senior vice president now owns 13,748 shares of the company’s stock, valued at $561,193.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.05% of the stock is owned by insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Featured Article: Trading Halts
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.